NCT06368440 - A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

December 23, 2024

Study Completion Date

December 23, 2024

Conditions

Healthy Participants

Interventions

DRUG

AZD6793

Participants will receive AZD6793 single dose as oral suspension.

DRUG

AZD6793

Participants will receive AZD6793 multiple doses daily as oral suspension.

DRUG

Placebo

Participants will receive matching doses of placebo as oral suspension.

Trial Locations (1)

Research Site, Glendale